Welcome to our dedicated page for Avita Medical SEC filings (Ticker: RCEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Scrolling through Avita Medical’s dense SEC documents to verify RECELL sales momentum or new FDA milestones can drain hours. Clinical trial disclosures, royalty triggers, and share issuances are scattered across multiple forms, and insider trading activity often arrives without context.
Stock Titan solves this complexity. Our AI-powered summaries turn the most technical statements in an Avita Medical annual report 10-K simplified, each Avita Medical quarterly earnings report 10-Q filing, and every Avita Medical 8-K material events explained into clear, plain-English insights. Need real-time alerts? The platform delivers Avita Medical Form 4 insider transactions real-time, so you can spot executive stock moves the moment they hit EDGAR.
Here’s what you can expect:
- 10-K & 10-Q – Track RECELL revenue by indication, R&D spend, and cash runway with Avita Medical earnings report filing analysis.
- 8-K – Understand material events like FDA guidance letters or pivotal trial updates in minutes.
- Form 4 – Follow Avita Medical insider trading Form 4 transactions to gauge management’s confidence.
- DEF 14A – Review Avita Medical proxy statement executive compensation without wading through legal language.
Whether you are understanding Avita Medical SEC documents with AI for the first time or comparing quarters, our real-time feed and expert commentary surface the details that matter—RECELL adoption rates, clinical spend, and any executive stock transactions Form 4 that could signal future direction. No more searching form by form; the answers are already highlighted, explained simply, and updated the instant the company files.
AVITA Medical (RCEL) filed its Q3 2025 10‑Q, reporting lower revenue and a going concern warning. Total revenue was $17.1 million for the quarter, down from $19.5 million a year ago. Net loss was $13.2 million versus $16.2 million in the prior year period. For the nine months, revenue reached $54.0 million and net loss was $37.0 million.
Cash, cash equivalents, and marketable securities were $23.3 million as of September 30, 2025. The company disclosed “substantial doubt” about its ability to continue as a going concern due to expected non‑compliance with a minimum cash covenant under its senior secured credit facility. The loan facility balance of $42.4 million was classified as current. AVITA obtained revenue covenant waivers for Q1–Q3 2025 and amended future thresholds.
To bolster liquidity, AVITA completed an August 12, 2025 private placement raising $14.8 million gross (3,440,377 common share equivalents via 17,201,886 CDIs). Shares outstanding were 30,493,111 as of November 3, 2025. Lease revenue from RECELL GO devices was $165,000 in Q3, with product sales the primary driver of revenue.
AVITA Medical (RCEL) amended its credit agreement with affiliates of OrbiMed Advisors, LLC. The Sixth Amendment sets a trailing 12‑month revenue covenant of $70.0 million for the quarter ending December 31, 2025, while keeping subsequent revenue covenants in place through the Maturity Date.
The lenders also waived a requirement that AVITA’s Form 10‑Q for the quarter ended September 30, 2025 contain no “going concern” or similar qualification. In exchange, AVITA agreed to add $500,000 to the principal balance of the Credit Agreement, with interest on this amount accruing as of November 1, 2025 and payable with the original $40,000,000 principal at maturity or earlier repayment.
Separately, AVITA announced it issued a press release covering third‑quarter results for the period ended September 30, 2025.
BlackRock, Inc. filed an amended Schedule 13G reporting beneficial ownership of 1,138,436 shares of AVITA Medical, Inc. (RCEL) common stock, representing 4.3% of the class. The event triggering the filing is dated 09/30/2025.
BlackRock reports sole voting power over 1,119,786 shares and sole dispositive power over 1,138,436 shares, with 0 shared voting or dispositive power. The filing notes that various persons may have rights to dividends or proceeds, but no single person exceeds five percent of outstanding shares. BlackRock certifies the securities were acquired and are held in the ordinary course of business and not to change or influence control.
AVITA Medical (RCEL) announced leadership changes. Effective October 16, 2025, James Corbett departed as Chief Executive Officer and director; the company stated his departure was not due to any disagreement regarding operations, policies, or practices. The Board appointed Chairman Cary Vance as Interim CEO, and named Jan Reed as Lead Independent Director.
Vance brings nearly 30 years of healthcare leadership experience, including CEO roles at PhotoniCare, Titan Medical, and others. As Interim CEO, he will receive an annual base salary of $702,000 and a guaranteed bonus of $140,000 for fiscal 2025. For fiscal 2026, he is eligible for a target bonus equal to 80% of base salary, with half guaranteed and half tied to performance metrics, subject to continued service through the one-year anniversary of the effective date. He will forgo Board compensation while serving as Interim CEO and will be reimbursed for commuting expenses per company policy.
Avita Medical director Robert McNamara reported a personal purchase of company stock on 08/28/2025. The Form 4 shows a purchase of 10,000 shares of Avita Medical common stock at $4.50 per share. After the transaction he beneficially owns 86,771 shares, a figure the filing notes includes unvested restricted stock units. The filing identifies McNamara as a director and was signed by an authorized power of attorney on 08/29/2025. The document lists no derivative transactions and provides no additional financial results or forward-looking statements.
Insider purchase reported: Avita Medical (RCEL) CFO David O'Toole purchased 2,000 shares of the company's common stock on 08/26/2025 at a price of $4.52 per share. After the transaction he beneficially owns 31,657 shares in a direct capacity. The filing shows no amendments and no derivative transactions were reported.
Avita Medical, Inc. (RCEL) director Robert McNamara reported a purchase of 10,000 shares of the company's common stock on 08/19/2025 at a price of $5.00 per share, bringing his beneficial ownership to 76,771 shares. The Form 4 was signed by power of attorney on 08/20/2025.
David O'Toole, identified as the Chief Financial Officer, filed a Form 4 reporting a change in beneficial ownership of Avita Medical, Inc. (RCEL). The filing shows he acquired 2,000 shares of common stock on 08/12/2025 at a price of $4.81 per share, increasing his direct holdings to 29,657 shares. The transaction is reported under transaction code P and the Form 4 was filed by one reporting person.
AVITA Medical, Inc. filed a Current Report on Form 8-K dated August 12, 2025, reporting that the company issued a press release announcing the successful completion of an equity raise in Australia. The filing states the press release is attached as Exhibit 99.1 and clarifies that the information furnished, including the exhibit, is not "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated. The 8-K is signed by Chief Financial Officer David O'Toole. The company's common stock trades under the symbol RCEL on Nasdaq.
FAQ
What is the current stock price of Avita Medical (RCEL)?
What is the market cap of Avita Medical (RCEL)?
